41st EORTC –PAMM winter meeting: February 13th-15th, 2020 in Stockholmfebbraio 15, 2020
During the last decade novel anticancer treatments have emerged from advances in understanding of tumor biology, and a number of molecular targets have been identified. New drugs have been developed to attack these targets. They are used to neutralize specific molecules or genes involved in cancer development (“targeted therapy”). To date, only a few of these agents can offer hope of a substantial impact on the natural history of the disease.
One of the reasons for the relative failure of the first generation of clinical trials of targeted therapy could be the multilevel cross-stimulation among the targets of the new biological agents along several pathways of signal transduction involved in neoplastic events. Blocking only one of these pathways allows others to act as salvage mechanisms for cancer cells. Therefore, the study of key biomarkers and combinations of biological compounds with both chemotherapy and other targeting compounds is an essential issue in the novel treatment modalities against cancer.
For our ongoing studies on drug resistance and new models to test targeted antitumor agents we obtained a CCA Foundation grant. This was reported in the leaflet of the Foundation, distributed during the Amsterdam Marathon 2012
See: CCA leaflet